An overview of ghrelin O-acyltransferase inhibitors: a literature and patent review for 2010-2019

References

• Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660.
   PubMed Web of Science ®Google Scholar
• Korbonits M, Bustin SA, Kojima M, et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86(2):881–887.
   PubMed Web of Science ®Google Scholar
• Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141(11):4255–4261.
   PubMed Web of Science ®Google Scholar
• Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mrna of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87(6):2988–2991.
   PubMed Web of Science ®Google Scholar
• Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85(12):4908–4911.
   PubMed Web of Science ®Google Scholar
• Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806):908–913.
   PubMed Web of Science ®Google Scholar
• Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50(11):2540–2547.
   PubMed Web of Science ®Google Scholar
• Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409(6817):194–198.
   PubMed Web of Science ®Google Scholar
• Egido EM, Rodriguez-Gallardo J, Silvestre RA, et al. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur J Endocrinol. 2002;146(2):241–244.
   PubMed Web of Science ®Google Scholar
• Reimer MK, Pacini G, Ahren B. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology. 2003;144(3):916–921.
   PubMed Web of Science ®Google Scholar
• McFarlane MR, Brown MS, Goldstein JL, et al. Induced ablation of ghrelin cells in adult mice does not decrease food intake, body weight, or response to high-fat diet. Cell Metab. 2014;20(1):54–60.
   PubMed Web of Science ®Google Scholar
• Abizaid A, Hougland JL. Ghrelin signaling: GOAT and GHS-R1a take a leap in complexity. Trends Endocrinol Metab. 2020;31(2):107–117.
   PubMed Web of Science ®Google Scholar
• Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37(4):649–661.
   PubMed Web of Science ®Google Scholar
• Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide y and agouti-related protein. Endocrinology. 2004;145(6):2607–2612.
   PubMed Web of Science ®Google Scholar
• Kohno D, Sone H, Tanaka S, et al. AMP-activated protein kinase activates neuropeptide Y neurons in the hypothalamic arcuate nucleus to increase food intake in rats. Neurosci Lett. 2011;499(3):194–198.
   PubMed Web of Science ®Google Scholar
• Kohno D, Sone H, Minokoshi Y, et al. Ghrelin raises [Ca2+]i via AMPK in hypothalamic arcuate nucleus NPY neurons. Biochem Biophys Res Commun. 2008;366(2):388–392.
   PubMed Web of Science ®Google Scholar
• Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem. 2004;279(13):12005–12008.
   PubMed Web of Science ®Google Scholar
• Anderson KA, Ribar TJ, Lin F, et al. Hypothalamic camkk2 contributes to the regulation of energy balance. Cell Metab. 2008;7(5):377–388.
   PubMed Web of Science ®Google Scholar
• Zhao TJ, Liang G, Li RL, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci U S A. 2010;107(16):7467–7472.
   PubMed Web of Science ®Google Scholar
• Xie TY, Ngo ST, Veldhuis JD, et al. Effect of deletion of ghrelin-O-acyltransferase on the pulsatile release of growth hormone in mice. J Neuroendocrinol. 2015;27(12):872–886.
   PubMed Web of Science ®Google Scholar
• Tschop M, Statnick MA, Suter TM, et al. GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002;143(2):558–568.
   PubMed Web of Science ®Google Scholar
• Broglio F, Gottero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab. 2004;89(6):3062–3065.
   PubMed Web of Science ®Google Scholar
• Diano S, Farr SA, Benoit SC, et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci. 2006;9(3):381–388.
   PubMed Web of Science ®Google Scholar
• Hsu TM, Suarez AN, Kanoski SE. Ghrelin: a link between memory and ingestive behavior. Physiol Behav. 2016;162:10–17.
   PubMed Web of Science ®Google Scholar
• Serrenho D, Santos SD, Carvalho AL. The role of ghrelin in regulating synaptic function and plasticity of feeding-associated circuits. Front Cell Neurosci. 2019;13:205.
   PubMed Web of Science ®Google Scholar
• Panagopoulos VN, Ralevski E. The role of ghrelin in addiction: a review. Psychopharmacology (Berl). 2014;231(14):2725–2740.
   PubMed Web of Science ®Google Scholar
• Lutter M, Sakata I, Osborne-Lawrence S, et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci. 2008;11(7):752–753.
   PubMed Web of Science ®Google Scholar
• Meyer RM, Burgos-Robles A, Liu E, et al. A ghrelin-growth hormone axis drives stress-induced vulnerability to enhanced fear. Mol Psychiatry. 2014;19(12):1284–1294.
   PubMed Web of Science ®Google Scholar
• Harmatz ES, Stone L, Lim SH, et al. Central ghrelin resistance permits the overconsolidation of fear memory. Biol Psychiatry. 2017;81(12):1003–1013.
   PubMed Web of Science ®Google Scholar
• Yousufzai M, Harmatz ES, Shah M, et al. Ghrelin is a persistent biomarker for chronic stress exposure in adolescent rats and humans. Transl Psychiatry. 2018;8(1):74.
   PubMedGoogle Scholar
• Cameron KO, Bhattacharya SK, Loomis AK. Small molecule ghrelin receptor inverse agonists and antagonists. J Med Chem. 2014;57(21):8671–8691.
   PubMed Web of Science ®Google Scholar
• McGovern KR, Darling JE, Hougland JL. Progress in small molecule and biologic therapeutics targeting ghrelin signaling. Mini Rev Med Chem. 2016;16(6):465–480.
   PubMed Web of Science ®Google Scholar
• Collden G, Tschop MH, Muller TD. Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci. 2017;18(4):798.
   Web of Science ®Google Scholar
• Howick K, Griffin BT, Cryan JF, et al. From belly to brain: targeting the ghrelin receptor in appetite and food intake regulation. Int J Mol Sci. 2017;18(2):273.
   Web of Science ®Google Scholar
• Avau B, Carbone F, Tack J, et al. Ghrelin signaling in the gut, its physiological properties, and therapeutic potential. Neurogastroenterol Motil. 2013;25(9):720–732.
   PubMed Web of Science ®Google Scholar
• Chollet C, Meyer K, Beck-Sickinger AG. Ghrelin–a novel generation of anti-obesity drug: design, pharmacomodulation and biological activity of ghrelin analogues. J Pept Sci. 2009;15(11):711–730.
   PubMed Web of Science ®Google Scholar
• Costantino L, Barlocco D. New perspectives on the development of antiobesity drugs. Future Med Chem. 2015;7(3):315–336.
   PubMed Web of Science ®Google Scholar
• Yang J, Brown MS, Liang G, et al. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell. 2008;132(3):387–396.
   PubMed Web of Science ®Google Scholar
• Gutierrez JA, Solenberg PJ, Perkins DR, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci U S A. 2008;105(17):6320–6325.
   PubMed Web of Science ®Google Scholar
• Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85(2):495–522.
   PubMed Web of Science ®Google Scholar
• Darling JE, Zhao F, Loftus RJ, et al. Structure-activity analysis of human ghrelin O-acyltransferase reveals chemical determinants of ghrelin selectivity and acyl group recognition. Biochemistry. 2015;54(4):1100–1110.
   PubMed Web of Science ®Google Scholar
• Gahete MD, Cordoba-Chacon J, Salvatori R, et al. Metabolic regulation of ghrelin O-acyl transferase (GOAT) expression in the mouse hypothalamus, pituitary, and stomach. Mol Cell Endocrinol. 2010;317(1–2):154–160.
   PubMed Web of Science ®Google Scholar
• Zhu X, Cao Y, Voogd K, et al. On the processing of proghrelin to ghrelin. J Biol Chem. 2006;281(50):38867–38870.
   PubMed Web of Science ®Google Scholar
• Delhanty PJ, Huisman M, Julien M, et al. The acylated (AG) to unacylated (UAG) ghrelin ratio in esterase inhibitor-treated blood is higher than previously described. Clin Endocrinol (Oxf). 2015;82(1):142–146.
   PubMed Web of Science ®Google Scholar
• De Vriese C, Gregoire F, Lema-Kisoka R, et al. Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology. 2004;145(11):4997–5005.
   PubMed Web of Science ®Google Scholar
• Satou M, Sugimoto H. The study of ghrelin deacylation enzymes. Methods Enzymol. 2012;514:165–179.
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Chen VP, Pang YP, et al. Physiological roles for butyrylcholinesterase: a BCHE-ghrelin axis. Chem Biol Interact. 2016;259(Pt B):271–275.
   PubMedGoogle Scholar
• Chen VP, Gao Y, Geng L, et al. Butyrylcholinesterase regulates central ghrelin signaling and has an impact on food intake and glucose homeostasis. Int J Obes (Lond). 2017;41(9):1413–1419.
   PubMed Web of Science ®Google Scholar
• Gauna C, Meyler FM, Janssen JA, et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab. 2004;89(10):5035–5042.
   PubMed Web of Science ®Google Scholar
• Gauna C, Kiewiet RM, Janssen JAMJL, et al. Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol-Endoc M. 2007;293(3):E697–E704.
   PubMed Web of Science ®Google Scholar
• Taylor MS, Ruch TR, Hsiao PY, et al. Architectural organization of the metabolic regulatory enzyme ghrelin O-acyltransferase. J Biol Chem. 2013;288(45):32211–32228.
   PubMed Web of Science ®Google Scholar
• Matevossian A, Resh MD. Membrane topology of hedgehog acyltransferase. J Biol Chem. 2015;290(4):2235–2243.
   PubMed Web of Science ®Google Scholar
• Konitsiotis AD, Jovanovic B, Ciepla P, et al. Topological analysis of hedgehog acyltransferase, a multipalmitoylated transmembrane protein. J Biol Chem. 2015;290(6):3293–3307.
   PubMed Web of Science ®Google Scholar
• Joyce CW, Shelness GS, Davis MA, et al. ACAT1 and ACAT2 membrane topology segregates a serine residue essential for activity to opposite sides of the endoplasmic reticulum membrane. Mol Biol Cell. 2000;11(11):3675–3687.
   PubMed Web of Science ®Google Scholar
• Lin S, Lu X, Chang CC, et al. Human acyl-coenzyme A: cholesterolacyltransferase expressed in chinese hamster ovary cells: membrane topology and active site location. Mol Biol Cell. 2003;14(6):2447–2460.
   PubMed Web of Science ®Google Scholar
• Pagac M, de la Mora HV, Duperrex C, et al. Topology of 1-acyl-sn-glycerol-3-phosphate acyltransferases SLC1 and ALE1 and related membrane-bound O-acyltransferases (MBOATs) of saccharomyces cerevisiae. J Biol Chem. 2011;286(42):36438–36447.
   PubMed Web of Science ®Google Scholar
• Ma D, Wang Z, Merrikh CN, et al. Crystal structure of a membrane-bound O-acyltransferase. Nature. 2018;562(7726):286–290.
   PubMed Web of Science ®Google Scholar
• Campana MB, Irudayanathan FJ, Davis TR, et al. The ghrelin O-acyltransferase structure reveals a catalytic channel for transmembrane hormone acylation. J Biol Chem. 2019;294(39):14166–14174.
   PubMed Web of Science ®Google Scholar
• Guan C, Niu Y, Chen S-C, et al. Inhibition mechanism of human sterol O-acyltransferase 1 by competitive inhibitor. bioRxiv. 2020. DOI:10.1101/2020.01.07.897124
   Google Scholar
• Perez-Tilve D, Heppner K, Kirchner H, et al. Ghrelin-induced adiposity is independent of orexigenic effects. Faseb J. 2011;25(8):2814–2822.
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Nelson TA, Guschina IA, et al. Unacylated ghrelin promotes adipogenesis in rodent bone marrow via ghrelin O-acyl transferase and GHS-R1a activity: evidence for target cell-induced acylation. Sci Rep. 2017;7:45541.
   PubMed Web of Science ®Google Scholar
• Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87(1):240–244.
   PubMed Web of Science ®Google Scholar
• Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707–709.
   PubMed Web of Science ®Google Scholar
• English PJ, Ghatei MA, Malik IA, et al. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002;87(6):2984–2987.
   PubMed Web of Science ®Google Scholar
• Barnett BP, Hwang Y, Taylor MS, et al. Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science. 2010;330(6011):1689–1692.
   PubMed Web of Science ®Google Scholar
• Wellman MK, Patterson ZR, MacKay H, et al. Novel regulator of acylated ghrelin, cf801, reduces weight gain, rebound feeding after a fast, and adiposity in mice. Front Endocrinol. 2015;6:144.
   PubMed Web of Science ®Google Scholar
• Soriano-Guillen L, Barrios V, Campos-Barros A, et al. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. J Pediatr. 2004;144(1):36–42.
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Herzog DB, et al. Growth hormone and ghrelin responses to an oral glucose load in adolescent girls with anorexia nervosa and controls. J Clin Endocrinol Metab. 2004;89(4):1605–1612.
   PubMed Web of Science ®Google Scholar
• Misra M, Klibanski A. Endocrine consequences of anorexia nervosa. Lancet Diabetes Endocrinol. 2014;2(7):581–592.
   PubMed Web of Science ®Google Scholar
• Fabbri AD, Deram S, Kerr DS, et al. Ghrelin and eating disorders. Arch Clin Psychiatry. 2015;42(2):52–62.
   Web of Science ®Google Scholar
• Schorr M, Miller KK. The endocrine manifestations of anorexia nervosa: mechanisms and management. Nat Rev Endocrinol. 2017;13(3):174–186.
   PubMed Web of Science ®Google Scholar
• Smitka K, Papezova H, Vondra K, et al. The role of “mixed” orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa. Int J Endocrinol. 2013;2013:483145.
   PubMedGoogle Scholar
• Berner LA, Brown TA, Lavender JM, et al. Neuroendocrinology of reward in anorexia nervosa and bulimia nervosa: beyond leptin and ghrelin. Mol Cell Endocrinol. 2019;497:110320.
   PubMed Web of Science ®Google Scholar
• Monteleone AM, Castellini G, Volpe U, et al. Neuroendocrinology and brain imaging of reward in eating disorders: a possible key to the treatment of anorexia nervosa and bulimia nervosa. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80(Pt B):132–142.
   PubMedGoogle Scholar
• Hotta M, Ohwada R, Akamizu T, et al. Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. Endocr J. 2009;56(9):1119–1128.
   PubMed Web of Science ®Google Scholar
• Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(6):2832–2836.
   PubMed Web of Science ®Google Scholar
• Haruta I, Fuku Y, Kinoshita K, et al. One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. J Cachexia Sarcopenia Muscle. 2015;6(3):237–241.
   PubMed Web of Science ®Google Scholar
• Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008;98(2):300–308.
   PubMed Web of Science ®Google Scholar
• Hassouna R, Labarthe A, Zizzari P, et al. Actions of agonists and antagonists of the ghrelin/GHS-R pathway on GH secretion, appetite, and cFos activity. Front Endocrinol (Lausanne). 2013;4:25.
   PubMedGoogle Scholar
• Holm VA, Cassidy SB, Butler MG, et al. Prader-willi syndrome: consensus diagnostic criteria. Pediatrics. 1993;91(2):398–402.
   PubMed Web of Science ®Google Scholar
• Lindgren AC, Barkeling B, Hagg A, et al. Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups. J Pediatr. 2000;137(1):50–55.
   PubMed Web of Science ®Google Scholar
• DelParigi A, Tschop M, Heiman ML, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab. 2002;87(12):5461–5464.
   PubMed Web of Science ®Google Scholar
• Haqq AM, Farooqi IS, O’Rahilly S, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(1):174–178.
   PubMed Web of Science ®Google Scholar
• Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med. 2002;8(7):643–644.
   PubMed Web of Science ®Google Scholar
• Feigerlova E, Diene G, Conte-Auriol F, et al. Hyperghrelinemia precedes obesity in Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93(7):2800–2805.
   PubMed Web of Science ®Google Scholar
• Kweh FA, Miller JL, Sulsona CR, et al. Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia. Am J Med Genet A. 2015;167A(1):69–79.
   PubMedGoogle Scholar
• Kuppens RJ, Diene G, Bakker NE, et al. Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome. Endocrine. 2015;50(3):633–642.
   PubMed Web of Science ®Google Scholar
• Beauloye V, Diene G, Kuppens R, et al. High unacylated ghrelin levels support the concept of anorexia in infants with Prader-Willi syndrome. Orphanet J Rare Dis. 2016;11(1):56.
   PubMedGoogle Scholar
• Haqq AM, Stadler DD, Rosenfeld RG, et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(8):3573–3576.
   PubMed Web of Science ®Google Scholar
• De Waele K, Ishkanian SL, Bogarin R, et al. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur J Endocrinol. 2008;159(4):381–388.
   PubMed Web of Science ®Google Scholar
• Lin D, Wang Q, Ran H, et al. Abnormal response to the anorexic effect of GHS-R inhibitors and exenatide in male snord116 deletion mouse model for Prader-Willi syndrome. Endocrinology. 2014;155(7):2355–2362.
   PubMed Web of Science ®Google Scholar
• Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron. 2002;36(2):229–240.
   PubMed Web of Science ®Google Scholar
• Martel P, Fantino M. Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. Pharmacol Biochem Behav. 1996;53(1):221–226.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Maynard L, et al. Brain dopamine is associated with eating behaviors in humans. Int J Eat Disord. 2003;33(2):136–142.
   PubMed Web of Science ®Google Scholar
• Wise RA. The role of reward pathways in the development of drug dependence. Pharmacol Ther. 1987;35(1–2):227–263.
   PubMed Web of Science ®Google Scholar
• Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8(11):1445–1449.
   PubMed Web of Science ®Google Scholar
• Jerlhag E, Egecioglu E, Dickson SL, et al. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict Biol. 2007;12(1):6–16.
   PubMed Web of Science ®Google Scholar
• Kraus T, Schanze A, Groschl M, et al. Ghrelin levels are increased in alcoholism. Alcohol Clin Exp Res. 2005;29(12):2154–2157.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Yoon SJ, Choi B, et al. Increased fasting plasma ghrelin levels during alcohol abstinence. Alcohol Alcohol. 2005;40(1):76–79.
   PubMed Web of Science ®Google Scholar
• Leggio L, Ferrulli A, Cardone S, et al. Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addict Biol. 2012;17(2):452–464.
   PubMed Web of Science ®Google Scholar
• Akkisi Kumsar N, Dilbaz N. Relationship between craving and ghrelin, adiponectin, and resistin levels in patients with alcoholism. Alcohol Clin Exp Res. 2015;39(4):702–709.
   PubMed Web of Science ®Google Scholar
• Hillemacher T, Kraus T, Rauh J, et al. Role of appetite-regulating peptides in alcohol craving: an analysis in respect to subtypes and different consumption patterns in alcoholism. Alcohol Clin Exp Res. 2007;31(6):950–954.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Capristo E, Leggio L, et al. Relationship between ghrelin levels, alcohol craving, and nutritional status in current alcoholic patients. Alcohol Clin Exp Res. 2006;30(11):1933–1937.
   PubMed Web of Science ®Google Scholar
• Koopmann A, Bach P, Schuster R, et al. Ghrelin modulates mesolimbic reactivity to alcohol cues in alcohol-addicted subjects: a functional imaging study. Addict Biol. 2019;24(5):1066–1076.
   PubMed Web of Science ®Google Scholar
• Bach P, Bumb JM, Schuster R, et al. Effects of leptin and ghrelin on neural cue-reactivity in alcohol addiction: two streams merge to one river? Psychoneuroendocrinology. 2019;100:1–9.
   PubMed Web of Science ®Google Scholar
• Davis KW, Wellman PJ, Clifford PS. Augmented cocaine conditioned place preference in rats pretreated with systemic ghrelin. Regul Pept. 2007;140(3):148–152.
   PubMedGoogle Scholar
• Wellman PJ, Hollas CN, Elliott AE. Systemic ghrelin sensitizes cocaine-induced hyperlocomotion in rats. Regul Pept. 2008;146(1–3):33–37.
   PubMedGoogle Scholar
• Jang JK, Kim WY, Cho BR, et al. Microinjection of ghrelin in the nucleus accumbens core enhances locomotor activity induced by cocaine. Behav Brain Res. 2013;248:7–11.
   PubMed Web of Science ®Google Scholar
• Tessari M, Catalano A, Pellitteri M, et al. Correlation between serum ghrelin levels and cocaine-seeking behaviour triggered by cocaine-associated conditioned stimuli in rats. Addict Biol. 2007;12(1):22–29.
   PubMed Web of Science ®Google Scholar
• Jerlhag E, Egecioglu E, Dickson SL, et al. Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference. Psychopharmacology (Berl). 2010;211(4):415–422.
   PubMed Web of Science ®Google Scholar
• Havlickova T, Charalambous C, Lapka M, et al. Ghrelin receptor antagonism of methamphetamine-induced conditioned place preference and intravenous self-administration in rats. Int J Mol Sci. 2018;19(10):2925–2946.
   Web of Science ®Google Scholar
• Jerlhag E, Engel JA. Ghrelin receptor antagonism attenuates nicotine-induced locomotor stimulation, accumbal dopamine release and conditioned place preference in mice. Drug Alcohol Depend. 2011;117(2–3):126–131.
   PubMed Web of Science ®Google Scholar
• Wellman PJ, Clifford PS, Rodriguez J, et al. Pharmacologic antagonism of ghrelin receptors attenuates development of nicotine induced locomotor sensitization in rats. Regul Pept. 2011;172(1–3):77–80.
   PubMedGoogle Scholar
• Sustkova-Fiserova M, Jerabek P, Havlickova T, et al. E.15 - ghrelin receptor antagonism attenuates morphine-induced accumbal dopamine release and behavioral stimulation in rats. 15th Biennial Meeting of the European Behavioural Pharmacology Society; 2013 Sept 6–9; La Rochelle; 2013.
   Google Scholar
• Sustkova-Fiserova M, Jerabek P, Havlickova T, et al. Ghrelin and endocannabinoids participation in morphine-induced effects in the rat nucleus accumbens. Psychopharmacology (Berl). 2016;233(3):469–484.
   PubMed Web of Science ®Google Scholar
• D’Cunha TM, Chisholm A, Hryhorczuk C, et al. A role for leptin and ghrelin in the augmentation of heroin seeking induced by chronic food restriction. Psychopharmacology (Berl). 2020;237(3):787–800.
   PubMed Web of Science ®Google Scholar
• Sustkova-Fiserova M, Puskina N, Havlickova T, et al. Ghrelin receptor antagonism of fentanyl-induced conditioned place preference, intravenous self-administration, and dopamine release in the nucleus accumbens in rats. Addict Biol. 2019;e12845. DOI:10.1111/adb.12845:e12845
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–1083.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Mari A. Beta-cell function in type 2 diabetes. Metabolism. 2014;63(10):1217–1227.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Heppner KM, Tong J. Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. Eur J Endocrinol. 2014;171(1):R21–R32.
   PubMed Web of Science ®Google Scholar
• Delhanty PJ. van der Lely AJ. Ghrelin and glucose homeostasis. Peptides. 2011;32(11):2309–2318.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ. Ghrelin and new metabolic frontiers. Horm Res. 2009;71(Suppl 1):129–133.
   PubMedGoogle Scholar
• van der Lely AJ, Tschop M, Heiman ML, et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25(3):426–457.
   PubMed Web of Science ®Google Scholar
• Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86(10):5083–5086.
   PubMed Web of Science ®Google Scholar
• Yada T, Damdindorj B, Rita RS, et al. Ghrelin signalling in beta-cells regulates insulin secretion and blood glucose. Diabetes Obes Metab. 2014;16(Suppl 1):111–117.
   PubMedGoogle Scholar
• Dezaki K, Hosoda H, Kakei M, et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes. 2004;53(12):3142–3151.
   PubMed Web of Science ®Google Scholar
• Barazzoni R, Zanetti M, Ferreira C, et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92(10):3935–3940.
   PubMed Web of Science ®Google Scholar
• Granata R, Settanni F, Julien M, et al. Des-acyl ghrelin fragments and analogues promote survival of pancreatic beta-cells and human pancreatic islets and prevent diabetes in streptozotocin-treated rats. J Med Chem. 2012;55(6):2585–2596.
   PubMed Web of Science ®Google Scholar
• Delhanty PJ, Huisman M, Baldeon-Rojas LY, et al. Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucose homeostasis. Faseb J. 2013;27(4):1690–1700.
   PubMed Web of Science ®Google Scholar
• Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59(9):2145–2151.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang X, Chen X, et al. Protein lipidation: occurrence, mechanisms, biological functions, and enabling technologies. Chem Rev. 2018;118(3):919–988.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhao T-J, Goldstein JL, et al. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U S A. 2008;105(31):10750–10755.
   PubMed Web of Science ®Google Scholar
• Yoneyama-Hirozane M, Deguchi K, Hirakawa T, et al. Identification and characterization of a new series of ghrelin O-acyl transferase inhibitors. SLAS Discovery. 2018;23(2):154–163.
   PubMed Web of Science ®Google Scholar
• Darling JE, Prybolsky EP, Sieburg M, et al. A fluorescent peptide substrate facilitates investigation of ghrelin recognition and acylation by ghrelin O-acyltransferase. Anal Biochem. 2013;437(1):68–76.
   PubMed Web of Science ®Google Scholar
• Hougland J, Darling J, inventors; Syracuse University, USA, assignee. Fluorescence assay for ghrelin O-acyltransferase activity. United States patent US 20140212904 B2. 2015 Aug 25.
   Google Scholar
• Zhao F, Darling JE, Gibbs RA, et al. A new class of ghrelin O-acyltransferase inhibitors incorporating triazole-linked lipid mimetic groups. Bioorg Med Chem Lett. 2015;25(14):2800–2803.
   PubMed Web of Science ®Google Scholar
• Hougland J, inventor; Syracuse University, USA, assignee. Inhibitors targeting human ghrelin O-acyltransferase. Unites States patent US 20150018520 A1. 2015 May 17.
   Google Scholar
• Cole PA, Barnett BP, Hwang Y, et al., inventors; The Johns Hopkins University, USA, assignee. Methods for synthesis and uses of peptide-coenzyme a conjugates as inhibitors of ghrelin O-acyltransferase as potential therapeutic agents for obesity and diabetes. World patent WO2010039461A2. 2010 Apr 8.
   Google Scholar
• Cole PA, Barnett BP, Hwang Y, et al., inventors; The Johns Hopkins University, USA, assignee. Methods for synthesis and uses of inhibitors of ghrelin O-acyltransferase as potential therapeutic agents for obesity and diabetes. United States patent US 20110257086 A1. 2011 Oct 20.
   Google Scholar
• Teubner BJW, Garretson JT, Hwang Y, et al. Inhibition of ghrelin O-acyltransferase attenuates food deprivation-induced increases in ingestive behavior. Horm Behav. 2013;63(4):667–673.
   PubMed Web of Science ®Google Scholar
• Bowers CY, Coy DH, Hocart SJ, et al., inventors; The Administrators of the Tulane Educational Fund, USA; McGill University, assignee. Methods of inhibiting the ghrelin/growth hormone secretagogue receptor pathway and uses thereof. World patent WO 2010132580 A2. 2010 Nov 18.
   Google Scholar
• Garner AL, Janda KD. A small molecule antagonist of ghrelin O-acyltransferase (GOAT). Chem Commun. 2011;47(26):7512–7514.
   PubMed Web of Science ®Google Scholar
• Garner AL, Janda KD. Cat-elcca: a robust method to monitor the fatty acid acyltransferase activity of ghrelin O-acyltransferase (GOAT). Angew Chem Int Ed. 2010;49(50):9630–9634.
   PubMed Web of Science ®Google Scholar
• Hollibaugh RA. Defining a minimal pharmacophore to selectively inhibit mboat4 [dissertation]. Los Angeles (CA): UCLA; 2016.
   Google Scholar
• Hollibaugh RA, Liu H, Elmajian N, et al., editors. Small molecule inhibitors of ghrelin O-acyl transferase. 243rd ACS National Meeting & Exposition; 2012 Mar 25–29; San Diego (CA): American Chemical Society; 2012.
   Google Scholar
• Harran PG, Brown MS, Goldstein JL, et al., inventors; University of Texas, USA, assignee. Small molecule inhibitors of ghrelin O-acyltransferase and therapeutic use thereof. United States patent US 20100086955 A1. 2010 Apr 8.
   Google Scholar
• Harran PG, Hollibaugh RA, Liu H, inventors; University of California, USA, assignee. Small lipopeptidomimetic inhibitors of ghrelin O-acyl transferase. World patent WO 2016044467 A1. 2016 Mar 24.
   Google Scholar
• McGovern-Gooch KR, Mahajani NS, Garagozzo A, et al. Synthetic triterpenoid inhibition of human ghrelin O-acyltransferase: the involvement of a functionally required cysteine provides mechanistic insight into ghrelin acylation. Biochemistry. 2017;56(7):919–931.
   PubMed Web of Science ®Google Scholar
• Sieburg MA, Cleverdon ER, Hougland JL. Biochemical assays for ghrelin acylation and inhibition of ghrelin O-acyltransferase. Methods Mol Biol. 2019;2009:227–241.
   PubMedGoogle Scholar
• Yates MS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of nrf2-regulated genes. Mol Cancer Ther. 2007;6(1):154–162.
   PubMed Web of Science ®Google Scholar
• Yore MM, Liby KT, Honda T, et al. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κb activation through direct inhibition of iκb kinase β. Mol Cancer Ther. 2006;5(12):3232–3239.
   PubMed Web of Science ®Google Scholar
• Honda T, Rounds BV, Gribble GW, et al. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett. 1998;8(19):2711–2714.
   PubMed Web of Science ®Google Scholar
• Wong MH, Bryan HK, Copple IM, et al. Design and synthesis of irreversible analogues of bardoxolone methyl for the identification of pharmacologically relevant targets and interaction sites. J Med Chem. 2016;59(6):2396–2409.
   PubMed Web of Science ®Google Scholar
• Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012;64(4):972–1003.
   PubMed Web of Science ®Google Scholar
• Jakob CG, Upadhyay AK, Donner PL, et al. Novel modes of inhibition of wild-type isocitrate dehydrogenase 1 (IDH1): direct covalent modification of His315. J Med Chem. 2018;61(15):6647–6657.
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Nakajima K, Uto T, et al. Bioactive triterpenes from the root of salvia miltiorrhiza bunge. Phytother Res. 2017;31(9):1457–1460.
   PubMed Web of Science ®Google Scholar
• Galka CS, Hembre EJ, Honigschmidt NA, et al., inventors; Eli Lilly and Company, USA, assignee. Preparation of n-acylamino acid derivatives as ghrelin O-acyl transferase inhibitors. World patent WO 2016168225 A1. 2016 Oct 20.
   Google Scholar
• Galka CS, Hembre EJ, Honigschmidt NA, et al., inventors; Eli Lilly and Company, USA, assignee. Preparation of 5-[2-[1-[n-acyl-l-alanyl]piperidin-4-yl]ethyl]-2-(trifluoromethyl)-6-methylpyrimidin-4-amine as ghrelin O-acyl transferase inhibitors. World patent WO 2016168222 A1. 2016 Oct 20.
   Google Scholar
• Martinez-Grau MA, inventor; Eli Lilly and Company, USA, assignee. Ghrelin O-acyl transferase inhibitor. United States patent US 20150133474 A1. 2015 May 14.
   Google Scholar
• Ruano G, Galka C, Hembre E, et al. Ghrelin O-acyl transferase (GOAT) inhibitors: optimization of the 6-chloro-2-methyl-5-[2-(4-piperidyl)ethyl]pyrimidin-4-amine scaffold. 252nd ACS National Meeting & Exposition; 2016 Aug 21–25; Philadelphia (PA): American Chemical Society; 2016.
   Google Scholar
• Martinez-Grau M, Dominguez C, Galka C, et al. Discovery and evaluation of the first small molecules targeting GOAT inhibition in vivo. 252nd ACS National Meeting & Exposition; 2016 Aug 21–25; Philadelphia (PA): American Chemical Society; 2016.
   Google Scholar
• Hembre E, Brier R, Chen Y, et al. Discovery of ly3073084, a novel non-peptide small molecule ghrelin-O-acyl transferase (GOAT) inhibitor. 252nd ACS National Meeting & Exposition; 2016 Aug 21–25; Philadelphia (PA): American Chemical Society; 2016.
   Google Scholar
• GLWL Research Inc. A study of GLWL-01 in patients with Prader-Willi syndrome. ClinicalTrials.gov Identifier: NCT03274856: GLWL Research Inc.; 2017–2019.
   Google Scholar
• Batterham R, Zakeri R. Investigating the role of ghrelin in regulating appetite and energy intake in patients following bariatric surgery (bari-insight). ClinicalTrials.gov Identifier: NCT03641417: University College, London; 2018–2019.
   Google Scholar
• Leggio L. Ghrelin signaling via GOAT inhibition in alcohol use disorder. ClinicalTrials.gov Identifier: NCT03896516: National Institute on Alcohol Abuse and Alcoholism (NIAAA); 2019–2020.
   Google Scholar
• Takakura N, Banno Y, Terao Y, et al., inventors; Takeda Pharmaceutical Company Limited, Japan, assignee. Preparation of benzothiophenyl- and benzofuranacetic acid derivatives as inhibitors of GOAT for treating obesity. World patent WO 2013125732 A1. 2013 Aug 29.
   Google Scholar
• Bandyopadhyay A, Cheung M, Eidam HS, et al., inventors; GlaxoSmithKline Intellectual Property Development Limited, UK, assignee. Preparation of ghrelin O-acyltransferase inhibitors for treatment of metabolic disorders. India patent IN 201811004277A. 2019 Aug 9.
   Google Scholar
• Bandyopadhyay A, Cheung M, Eidam HS, et al., inventors; GlaxoSmithΚline Intellectual Property Development Limited, UK, assignee. Preparation of ghrelin O-acyltransferase inhibitors for treatment of metabolic disorders. World patent WO 2019149959 A1. 2019 Aug 8.
   Google Scholar
• Wang L, inventor; Peop. Rep. China, assignee. Ghrelin O-acyltransferase (GOAT) inhibitor and its applications in obesity and diabetes. China patent CN 108516972A. 2018 Sept 11.
   Google Scholar
• Trieselmann T, Godbout C, Hoenke C, et al., inventors; Boehringer Ingelheim International GmbH, Germany, assignee. Preparation of benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors. World patent WO 2019149657 A1. 2019 Aug 8.
   Google Scholar
• Trieselmann T, Godbout C, Vintonyak V, inventors; Boehringer Ingelheim International GmbH, Germany, assignee. Preparation of heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase inhibitors. World patent WO 2019149659 A1. 2019 Aug 8.
   Google Scholar
• Trieselmann T, Godbout C, Hoenke C, et al., inventors; Boehringer Ingelheim International GmbH, Germany, assignee. Preparation of triazolopyrimidine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors. World patent WO 2019149660 A1. 2019 Aug 8.
   Google Scholar
• Godbout C, Trieselmann T, Vintonyak V, inventors; Boehringer Ingelheim International GmbH, Germany, assignee. Preparation of oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors. World patent WO 2018024653 A1. 2018 Feb 8.
   Google Scholar
• Godbout C, Trieselmann T, Vintonyak V, inventors; Boehringer Ingelheim International GmbH, Germany, assignee. Preparation of heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase inhibitors. World patent WO 2019149658 A1. 2019 Aug 8.
   Google Scholar
• Resh MD. Fatty acylation of proteins: the long and the short of it. Prog Lipid Res. 2016;63:120–131.
   PubMed Web of Science ®Google Scholar
• Ho SY, Keller TH. The use of porcupine inhibitors to target wnt-driven cancers. Bioorg Med Chem Lett. 2015;25(23):5472–5476.
   PubMed Web of Science ®Google Scholar
• Resh MD. Palmitoylation of proteins in cancer. Biochem Soc Trans. 2017;45(2):409–416.
   PubMed Web of Science ®Google Scholar